Germany Drug Delivery Devices Market Analysis by Mordor Intelligence
The Germany drug delivery devices market is valued at USD 10.45 billion in 2025 and is forecast to reach USD 15.90 billion by 2030, registering an 8.75% CAGR. Continuous gains stem from the country’s broad statutory insurance coverage, strong manufacturing base in high-value syringes and autoinjectors, and an expanding pipeline of biologics that require precise administration technologies. High diabetes prevalence, a rising cancer burden, and Germany’s well-resourced hospital network keep demand for injectable systems elevated, while rapid shifts toward home-based care and sustainability goals are opening space for connected, reusable formats. EU-wide joint clinical assessments introduced in 2025, domestic fast-track pathways, and real-time digital adherence tools together shorten launch timelines and support uptake of next-generation devices, even as reference-price rules temper premium options.
Key Report Takeaways
- By device type, injectable delivery devices led with 43.45% of Germany drug delivery devices market share in 2024; implantable systems are projected to expand at an 10.24% CAGR to 2030.
- By route of administration, injectable routes accounted for 49.67% share of the Germany drug delivery devices market size in 2024, while transdermal delivery is advancing at a 10.03% CAGR through 2030.
- By application, diabetes captured 30.23% of Germany drug delivery devices market size in 2024; oncology exhibits the fastest growth at a 9.95% CAGR between 2025-2030.
- By end-user, hospitals held 42.55% revenue share in 2024, whereas homecare settings are set to grow at an 10.98% CAGR through 2030.
Germany Drug Delivery Devices Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
High Prevalence and Incidence of Chronic and Infectious Diseases | +1.8% | Germany, with spillover to broader EU healthcare systems | Long term (≥ 4 years) |
Growing Trend of Home Healthcare and Aging Population | +1.6% | Germany core, with demographic parallels across Western Europe | Medium term (2-4 years) |
Increasing Investment in Biosimilar and Biologics Product Innovation and Development | +1.4% | Germany & EU regulatory zones, global pharmaceutical hubs | Medium term (2-4 years) |
Government Initiatives Supporting Fast Track Approval and Reimbursement | +1.2% | Germany national, with EU harmonization effects | Short term (≤ 2 years) |
Technological Advancement and Digitalization | +1.1% | Global, with early adoption in Germany's industrial centers | Medium term (2-4 years) |
Expansion of Contract-Manufacturing Hubs | +0.9% | Germany & Central Europe manufacturing corridors | Long term (≥ 4 years) |
Source: Mordor Intelligence
High Prevalence and Incidence of Chronic and Infectious Diseases
Germany reports higher-than-EU-average prevalence for diabetes (8.4%), cardiovascular diseases (6.8%), and chronic respiratory diseases (11.4%).[1]Robert Koch Institute, “Health in Germany,” rki.de This chronic-disease load drives steady demand for advanced injectors, insulin pens, smart pumps, and sustained-release implants that improve adherence and outcomes. Diabetes alone is projected to affect 10.9-14.2 million Germans by 2040, pushing continuous upgrades in automated insulin delivery ecosystems. Oncology demand follows a similar path: micro-/nano-robots under development at the German Cancer Research Center aim to raise tumour-site uptake while cutting systemic toxicity.[2]German Cancer Research Center, “Smart Technologies for Tumor Therapy,” dkfz.de Together, disease trends and research breakthroughs keep the Germany drug delivery devices market on an innovation-driven trajectory.
Growing Trend of Home Healthcare and Aging Population
People aged ≥ 65 will rise from 21% of the population in 2023 to nearly 30% by 2050. Concurrently, those requiring long-term care could climb to 14 million by 2050. These shifts amplify the need for devices that non-professionals can use safely in domestic settings. On-body injectors such as Gerresheimer’s Gx SensAir® allow weekly subcutaneous dosing of monoclonal antibodies without clinical visits, cutting travel-related emissions and easing caregiver burdens. Consumer familiarity with telehealth platforms further accelerates uptake of connected inhalers, pens, and patches that integrate adherence dashboards, reinforcing market momentum in Germany drug delivery devices market.
Increasing Investment in Biosimilar and Biologics Product Innovation and Development
Biopharma sponsors are funnelling capital into mRNA, GLP-1, and cell-and-gene therapies that demand sophisticated containers and administration tools. SCHOTT Pharma boosted revenue from prefillable syringes by 54% to EUR 344 million in 2024 after expanding domestic capacity. Its TOPPAC freeze polymer syringe tolerates cryogenic storage for mRNA vaccines, while cartriQ cartridges target insulin and large-molecule drugs. Continuous spending by industry players underpins steady growth in the Germany drug delivery devices market.
Government Initiatives Supporting Fast Track Approval and Reimbursement
The Medical Research Act (October 2024) slashes red tape for clinical trials and first-in-human studies, compressing development timelines.[3] Germany’s Digital-Health-Applications route reimburses lower-risk connected devices once positive care effect is proven, granting access to more than 90% of the insured population. Alignment with the EU Health Technology Assessment Regulation from 2025 streamlines post-launch benefit assessments, shortening the path from prototype to prescription and strengthening demand across the Germany drug delivery devices market.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Stringent Regulatory Requirements and Product Recalls | -1.3% | Germany national, with EU-wide regulatory alignment | Long term (≥ 4 years) |
G-BA Price Regulation Capping Premiums for Innovative Systems | -1.1% | Germany national, with potential EU policy spillover | Short term (≤ 2 years) |
Market Saturation in Conventional Systems Coupled with Patient Compliance and Acceptance Issues | -0.8% | Germany core, with similar patterns in mature European markets | Medium term (2-4 years) |
Limited Availability of Specialized Microfluidics & Combination-Product Engineering Talent | -0.6% | Germany & broader European technical talent pools | Long term (≥ 4 years) |
Source: Mordor Intelligence
Stringent Regulatory Requirements and Product Recalls
Germany enforces EU Medical Device Regulation (MDR) alongside its Medical Device Law Implementation Act. Combination products must satisfy dual drug-device evidence packages, and higher-risk classes require third-party conformity assessments.[3]Federal Institute for Drugs and Medical Devices, “Medical Research Act,” bfarm.deResulting cost spikes and recall liabilities weigh heaviest on SMEs, occasionally pausing launches and trimming the Germany drug delivery devices market growth curve.
The Federal Joint Committee assigns reference groups that set maximum reimbursable prices; devices lacking additional benefit evidence must sit at least 10% below comparators. While confidential prices are possible for select innovations, many premium connected or implantable systems still face tight margins, dampening aggressive commercial rollouts in the Germany drug delivery devices market.
Segment Analysis
By Device Type: Injectable Systems Maintain Leadership as Implants Accelerate
Injectable devices represented 43.45% of all revenues in 2024, cementing their role in the Germany drug delivery devices market size. Sustained demand arises from biologic therapies that dominate new drug approvals and from continuing preference among clinicians for parenteral accuracy. SCHOTT Pharma’s capacity surge in polymer and glass syringes underscores industry confidence.
Implantable pumps, micro-chips, and bioresorbable depots post the quickest gains at an 10.24% CAGR. Patient-friendly inhalers preserve share amid a high national burden of chronic respiratory illness, while transdermal patches earn incremental adoption for hormone and pain management. Across categories, embedded connectivity features enhance dose logging and feedback loops, lifting adherence and data-driven care pathways within the Germany drug delivery devices market.
Note: Segment shares of all individual segments available upon report purchase
By Route of Administration: Injectable Dominance with Transdermal Upswing
Injectable delivery retained a 49.67% revenue stake in 2024, reflecting clinician trust in intravenous, subcutaneous, and intramuscular routes for vaccines and large-molecule drugs. This proportion anchors the Germany drug delivery devices market share and is bolstered by next-gen autoinjectors that lower activation force and support 2-5 mL volumes.
Transdermal formats scale fastest at a 10.03% CAGR on the back of microneedle arrays and wirelessly powered acoustic patches that raise payload size limits. Oral mucosal films gain traction for rapid pain relief, while inhaled, ocular, and nasal modalities extend options for targeted local therapy, together enriching clinical toolkits available to practitioners in the Germany drug delivery devices market.
Note: Segment shares of all individual segments available upon report purchase
By Application: Diabetes Commands Revenues while Oncology Propels Future Growth
Diabetes accounted for 30.23% of the Germany drug delivery devices market size in 2024. Closed-loop AID systems that synchronise CGM and pump algorithms are now widely prescribed, with paediatric guidelines highlighting superior time-in-range during exercise scenarios.
Oncology devices advance at a 9.95% CAGR as micro-robots, nanoparticle shuttles, and on-body injectors aim to chip away at hospital infusion visits. Cardiovascular, respiratory, and CNS segments maintain steady share, whereas infectious-disease applications spur interest in single-use dual-chamber syringes that simplify lyophilised vaccine reconstitution in the Germany drug delivery devices market.
By End-user: Hospitals Reign but Homecare Gains Ground
Hospitals generated 42.55% of 2024 turnover, reflecting concentration of complex oncology and critical-care infusions. Integrated pharmacy automation and staff familiarity with multi-channel pumps reinforce their centrality.
Yet homecare settings are on a double-digit growth trajectory (10.98% CAGR) as statutory insurers reimburse nurse visits and connected devices for self-administration. Ambulatory surgical centres and specialist clinics fill the gap between inpatient and home use, widening distribution nodes for suppliers active in the Germany drug delivery devices market.

Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
Germany’s advanced hospital density, export-oriented manufacturing, and universal insurance base combine to support a vibrant domestic ecosystem for drug delivery innovation. Nationwide reimbursement rules guarantee broad patient access while price corridors guide cost containment, creating predictable albeit competitive revenue pools.
Urban Länder such as North-Rhine-Westphalia and Baden-Württemberg house clusters of device engineers, glass manufacturers, and pharma R&D hubs, accelerating prototype-to-pilot cycles. Eastern regions, historically underserved, are seeing targeted federal grants directed at digital-health rollouts and elder-care technology pilots, gradually balancing regional adoption.
The demographic reality of a median age nearing 47 and an expanding cohort of multimorbid seniors ensures enduring demand for both high-acuity hospital devices and simplified self-care formats. This blend of sophisticated infrastructure and home-centred preferences cements Germany’s role as the reference market for European launches and attracts cross-border investment into the Germany drug delivery devices market.
Competitive Landscape
The Germany drug delivery devices market is moderately fragmented: global pharma groups supply combination products, mid-sized German engineering firms specialise in precision components, and contract manufacturers offer scalable fill-and-finish services. Strategic alliances predominate. Gerresheimer’s tie-up with Aptar Digital Health pairs mechanical expertise with software analytics to deliver integrated oncology support tools.
SCHOTT Pharma, leveraging decades of glass science, is shifting toward polymer solutions fit for low-temperature biologics while expanding ready-to-use cartridge lines. Vetter invests in fill-finish expansions in Ravensburg and Langenargen to meet surging outsourcing orders for injectables. Start-ups focusing on microneedle and acoustic-patch platforms inject further dynamism.
Sustainability credentials are fast becoming bid criteria: on-body systems featuring reusable drive units and recyclable disposables align with hospital and insurer green targets. Meanwhile, price-reference caps prompt firms to highlight total-cost-of-care savings through adherence gains and reduced hospitalisations, sharpening competitive narratives across the Germany drug delivery devices market.
Germany Drug Delivery Devices Industry Leaders
-
Bayer AG
-
Becton, Dickinson and Company
-
Gerresheimer AG
-
Ypsomed Holding AG
-
Boehringer Ingelheim International GmbH
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- May 2025: SCHOTT Pharma introduced a 1.5 ml ready-to-use sterile cartridge in Germany, adding a compact option to its cartriQ line for stable storage of insulin, GLP-1 therapies and hormones.
- March 2025: Dexcom revealed new integrations allowing its G7 continuous glucose monitor to link directly with Novo Nordisk’s smart insulin pens, NovoPen 6 and NovoPen Echo Plus, bringing real-time glucose data and dosing closer together.
- January 2025: BioNxt Solutions will transfer its drug-delivery R&D activities to Gen-Plus CRDO in Munich on 1 March 2025, a move aimed at accelerating development milestones.
- June 2024: Vetter announced it is relocating its Development Services site from Skokie, Illinois, to Des Plaines and expanding manufacturing capacity in Ravensburg and Langenargen, Germany, to meet rising demand for outsourced injectable production.
Germany Drug Delivery Devices Market Report Scope
As per the scope, drug delivery devices or system are the tools which are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The Germany Drug Delivery Devices Market is segmented By Route of Administration, Application, and End User.
By Device Type | Injectable Delivery Devices |
Inhalation Delivery Devices | |
Infusion Pumps | |
Transdermal Patches | |
Implantable Drug Delivery Systems | |
Ocular Inserts & Delivery Implants | |
Nasal & Buccal Delivery Devices | |
By Route of Administration | Injectable |
Inhalation | |
Transdermal | |
Oral Mucosal (Buccal and Sublingual) | |
Ocular | |
Nasal | |
By Application | Diabetes |
Oncology | |
Cardiovascular | |
Respiratory | |
Central Nervous System Disorders | |
Infectious Diseases | |
Others | |
By End-user | Hospitals |
Ambulatory Surgical Centres | |
Homecare Settings | |
Clinics and Speciality Centres | |
Others |
Injectable Delivery Devices |
Inhalation Delivery Devices |
Infusion Pumps |
Transdermal Patches |
Implantable Drug Delivery Systems |
Ocular Inserts & Delivery Implants |
Nasal & Buccal Delivery Devices |
Injectable |
Inhalation |
Transdermal |
Oral Mucosal (Buccal and Sublingual) |
Ocular |
Nasal |
Diabetes |
Oncology |
Cardiovascular |
Respiratory |
Central Nervous System Disorders |
Infectious Diseases |
Others |
Hospitals |
Ambulatory Surgical Centres |
Homecare Settings |
Clinics and Speciality Centres |
Others |
Key Questions Answered in the Report
1. What is the current value of the Germany drug delivery devices market?
The market stands at USD 10.45 billion in 2025 and is projected to grow to USD 15.90 billion by 2030.
2. Which device type generates the highest revenue?
Injectable systems lead with a 43.45% share due to their central role in biologics and chronic-disease therapy.
3. How fast is the homecare segment growing?
Home-based use of drug delivery devices is advancing at an 10.98% CAGR through 2030 on the back of demographic ageing and telehealth adoption.
4. Why are transdermal patches gaining popularity?
New microneedle and acoustic-wave technologies boost skin permeation while offering painless, self-administered dosing.
5. What role do German regulations play in device approvals?
The Medical Research Act and EU HTA alignment shorten clinical-trial and reimbursement timelines, although stringent MDR requirements still raise development costs.
6. Which therapeutic area shows the fastest growth?
Oncology devices post a 9.95% CAGR thanks to micro-robotic carriers and on-body injectors aimed at precise tumour targeting
Page last updated on: June 6, 2025